A new boxed warning for lactic acidosis was added to the label for Metformin Hydrochloride, effective 2026-05-22. This significant label revision highlights the serious risk of metformin-associated lactic acidosis, which has been observed in postmarketing cases and has resulted in severe outcomes including death, hypothermia, hypotension, and resistant bradyarrhythmias. The warning also notes that the onset of this condition is often subtle.
What this means
The updated label for Metformin Hydrochloride now includes a prominent boxed warning, serving as a critical alert for healthcare providers and patients regarding the risk of lactic acidosis. This warning directly stems from postmarketing surveillance, which has identified cases where metformin-associated lactic acidosis led to severe and often fatal consequences. Specific outcomes cited include death, hypothermia, hypotension, and resistant bradyarrhythmias. The emphasis on the subtle onset of lactic acidosis is crucial, as it implies that early symptoms may be non-specific, making timely diagnosis and intervention challenging. Clinicians are advised to maintain a high index of suspicion for lactic acidosis in patients receiving Metformin Hydrochloride, especially those with predisposing factors. Understanding these potential complications is vital for patient safety and appropriate management strategies.
Source
The information regarding this label revision was obtained from the FDA, as detailed in the official label update for Metformin Hydrochloride. This revision, which became effective on 2026-05-22, is publicly accessible on the dailymed.nlm.nih.gov website. The specific document is identified by the setid a944a167-e3ac-4084-af1c-22b48713471c, providing a verifiable source for the updated safety information.